These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Norata GD; Tibolla G; Catapano AL Vascul Pharmacol; 2014 Aug; 62(2):103-11. PubMed ID: 24924410 [TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). Ferdinand KC; Nasser SA Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408 [TBL] [Abstract][Full Text] [Related]
13. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
15. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Ling H; Burns TL; Hilleman DE Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905 [TBL] [Abstract][Full Text] [Related]
16. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
17. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Seidah NG; Abifadel M; Prost S; Boileau C; Prat A Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219 [TBL] [Abstract][Full Text] [Related]
18. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?]. Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302 [TBL] [Abstract][Full Text] [Related]
19. The Evolving Future of PCSK9 Inhibitors. Rosenson RS; Hegele RA; Fazio S; Cannon CP J Am Coll Cardiol; 2018 Jul; 72(3):314-329. PubMed ID: 30012326 [TBL] [Abstract][Full Text] [Related]
20. [Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich]. Erbel R; Gitt AK Herz; 2016 Jun; 41(4):271-2. PubMed ID: 27241696 [No Abstract] [Full Text] [Related] [Next] [New Search]